Hemostatic, antiseptic and wound healing sponge |
|
|
IPC classes for russian patent Hemostatic, antiseptic and wound healing sponge (RU 2226406):
 The method of closing and treatment of wound surfaces and floor for its implementation / 2166963
The invention relates to medicine, namely to means for closing and treatment of wounds of various etiologies, and allows you to accelerate the healing process, to protect against the occurrence of infection and the appearance of scars
Hydrocolloid coating application / 2219955
The invention relates to medicine, namely to hydrocolloid application to coatings based on chitosan containing polyvinyl alcohol, chitosan, organic acid, the biologically active substance, glutaric aldehyde, ethyl alcohol and water, is intended for use in the treatment process to accelerate epithelialization of wounds of different origin and localization on the body, as a means of preventing the formation of hypertrophic and keloid scars, improve trophism of the skin and mucous membranes, can be used hyperkeratosis, age-related pathology of the skin
The method of treatment of uterine cervix / 2217150
The invention relates to medicine, in particular to gynecology
Method of preventing recurrent bleeding from peptic ulcers of the stomach and duodenum / 2209638
The invention relates to medicine, in particular to surgery, and can be used for prevention of recurrent bleeding from peptic ulcers of the stomach and duodenum
 A hemostatic sponge and method of reception / 2198684
The invention relates to medicine, in particular to the hemostatic tools used in the surgery, at home, etc
A hemostatic sponge, based on collagen, its preparation, dressing for wounds, including such sponge, and set for making dressings for wounds / 2193897
The invention relates to medicine, namely to hemostatic sponges based on collagen and the activator or proactivate blood clotting, uniformly distributed therein, which is dried and contains at least 2% of water, preferably in the range of 2 to 25%, more preferably from 10 to 20%, and to a method for producing such sponges
 Coating for wounds / 2193895
 The film, giving the shrinkage in water / 2183470
The invention relates to a flexible polymeric film that quickly shrinks in size when it is immersed in water
 A wound healing agent / 2180241
The invention relates to medicine and biotechnology and can be used in surgery and for the treatment of burns as a wound healing material in the treatment of infected wounds and burns
The method of obtaining collagen materials / 2174410
The invention relates to methods for biocomposite materials based on collagen, used in medicine, namely for reconstructive surgery
For the treatment of wounds / 2154497
 Method for obtaining artificial skin matrix / 2252787
The present innovation deals with restoring artificial matrix of dermal-epidermal skin equivalent. The method, also, deals with mixing both collagen and chitosan by adding a surface-active substance and a binding agent followed by pouring the mixture obtained, its freezing followed by freeze drying and gamma-sterilization, moreover, before obtaining polyelectrolytic complex of collagen and chitosan one should successively supplement chitosan with aqueous solutions of 1.8 g/g dry chitosan of ascorbic acid, 5-100 mg/g dry chitosan of chondroitin sulfuric acid, 10-100 mg/g dry chitosan of hyaluronic (D-glucuronic) acid, 11-220 mcg/g dry chitosan of cattle serumal growth factor and 2.5-5 mg/g dry chitosan of heparin. The method provides to obtain a structure similar to skin that substitutes skin defect perfectly.
 Wound coat based on collagen-chitosan complex / 2254145
Claimed wound coat in form of sponge, gel, colloid solution, film contains chitosan with deacetylation ratio of 0.95-0.99 and molecular weight of 10-1000 kDa in form of chitosan ascorbate containing (in 1 g of dry chitosan): ascorbic acid 1.8 g; as well as chondroitinsulfuric acid 500-100 mg; hyaluronic acid 10-100 mg; heparin 2.5-5 mg, and serum cattle growth factor 11-220 mum. Wound of present invention is useful in reduction of skin wound defects.
Medical bandage containing proteolytic enzyme complex including collagenolytic proteases from crab hepatopancreas / 2268751
Invention provides wound coating from chemically modified cellulose, to which enzymes, including collagenolytic ones constituting enzyme complex of crab hepatopancreas, are added by way of chemical bonds formation. Method of making such bandage is also claimed.
 Method for local chemotherapy of cerebral tumors / 2284815
The present innovation deals with local chemotherapy of malignant cerebral tumors. Thus, after removing the tumor one should apply a collagen hemostatic sponge with a cavity inside it with a powder-like chemopreparation into tumor's bed, then the cavity should be covered with another fragment of collagen sponge. The innovation enables to minimize toxic manifestations of chemotherapy at applying maximal concentration of anti-tumor preparation.
Wound-healing sponge / 2308960
Invention relates to wound-healing collagen sponge. Wound-healing collagen sponge with the definite content of Bergenia pacifica black leaves extract is prepared by sublimation of mixture of 2% collagen solution, purified water and Bergenia pacifica black leaves dry extract for a definite time followed by additional drying of prepared plates and conditioning under the definite conditions. Sponge possesses the expressed wound-healing activity in wound injuries.
 Biological bandage for treating burn injury cases / 2314129
Device has perforated polymer film from polycarboxyl-polycarbonate polymer having spongious coating. The spongious coating is not thicker than 1 mm and has native lyophilized collagen of type I impregnated with healthy donor blood serum having AB(IV) Rh- Kell- phenotypes. The biological bandage is applied 1-2 times a day after burn injury, that results in full-scale epithelium recovery without hypertrophic cicatrix being formed.
 Osteoinducing material (variants) / 2317088
In the first embodiment claimed material includes hydroxyapatite with tricalcium phosphate and additionally it contains osteogenesis-inducing composition of non-collagen bone tissue proteins in specific component ratio per 100 g of material. In the second embodiment claimed material includes hydroxyapatite with tricalcium phosphate and/or collagen and additionally it contains osteogenesis-inducing composition of non-collagen bone tissue proteins. In the third embodiment claimed material includes hydroxyapatite with tricalcium phosphate and/or collagen and additionally it contains osteogenesis-inducing composition of non-collagen bone tissue proteins and double distilled water in specific component ratio per 100 g of material.
 Anti-aging and wound-healing compositions / 2318873
Disclosed are peptides derived from proenzyme forms of matrix proteinases which represent inhibitors of matrix proteinases. Amino acid sequence is disclosed in description. Described are composition for stimulation of healthy skin formation, containing therapeutically effective amount of peptides. Also disclosed are dressing for wounds, method for stimulation of healthy skin formation and wound healing. Disclosed is using of composition in production of drug for wound healing.
Medical bandage containing exzyme complex from hepatopancreas of crab, and method of its preparation / 2323748
Medical bandage from chemically modified cellulose, which contains the immobilized chitosan, and which has the enzymes attached to it via chemical bonds, among those proteolytic, elastolytic and collagenolytic that constitute the enzyme complex of crab hepatopancreas. Also, the method of bandage preparation is described.
|
(57) Abstract: The invention relates to medicine, particularly to hemostatic tool for the treatment of wounds of various etiologies. The invention consists in the fact that the proposed antiseptic and wound-healing hemostatic sponge containing as the basis of gelatin, active component, furatsilin and additionally methyluracil at a certain ratio of components. As the active component sponge preferably contains kanamycin sulfate. The sponge may additionally contain calcium chloride in an amount of not more than 0.5 wt.% in relation to gelatine. The sponge has a high therapeutic and hemostatic efficacy. 2 C.p. f-crystals. The invention relates to medicine, in particular to the means used to stop bleeding, the treatment of burns and wounds, and integrated local treatment of patients with trophic ulcers, bedsores, radiation damages the skin. In addition, this tool can be successfully used as a local hemostatic and healing agents in the field. Currently, surgical and medical practice promising dosage form is referred bleeding, to protect the wound from secondary infection, reduce pain and promote wound healing. This reduces the cost of the dressing material in 2-4 times and reduces the number of costly hospital days more than 2 times. To enhance therapeutic effectiveness of the composition of said funds administered pharmacologically active components-antiseptics, antibiotics, biostimulants and other auxiliary additives (patents of the Russian Federation№№ 2034572, 10.05.95; 2053796, 10.02.96; 2071788, 20.01.97, class a 61 L 15/32, 15/44). Known absorbable hemostatic sponge on the basis of dried, purified gelatin foam, having a homogeneous porous structure (Advertising Avenue. Absorbable hemostatic sponge - standard /special/ film "Spongostan" is a trademark. "Ferrosan", Denmark. Representation "Johnson & Johnson", , Moscow). Thanks to its structure, the sponge keeps the platelets and activates them, resulting in the produced active substances that contribute to the natural coagulation. The quantity absorbed blood in 45 times the weight of the sponge. Applique sponge is dry or moistened with saline solution. Sponge fixed on the site of bleeding, and after a certain period of time nastupaet septicemic measures) and to close the wound. In the case of infected wounds of the sponge must be removed after the onset of hemostasis. However, despite the high efficiency of known hemostatic sponge "Spongostan" on gelatin-based, therapeutic range of its validity is limited, its main use is as hemostatic on different tissues of the body. In addition, its application in the domestic medical practice is virtually absent due to the high cost. Famous sponge with antiseptic hemostatic activity in accordance with VFS 42-1567-85 used as a medicinal product, which is the closest analogue to the technical nature of the claimed invention. This sponge contains gelatin food as the basis, kanamycin sulfate, furatsilin, calcium chloride and sultanol in the following ratio of components, g (composition per sponge): Kanamycin sulfate 37500 U Furatsilin 0,0015 Calcium chloride 0,0015 Sultanol 0,006 Food gelatin 0,6 On the basis of technological regulations developed in accordance with VFS 42-1567-85, the method of obtaining the hemostatic and antiseptic sponges involves swelling tion and antiseptics - sultanol NP-3. The resulting mixture is foamed to increase 3 times and enter kanamycin sulfate, pre-dissolved in distilled water. The mixture foamed to obtain a stable foam, is poured into the cuvette and dried by freezing at minus 50C for 5 days. The product is then placed in a vacuum dryer and dried for 30 h at the temperature from 45 CELSIUS to minus S. The finished dry product is cut into sheets of appropriate size, Packed in paper bags and sterilized by dry heat at 120C for 15 minutes This hemostatic and antiseptic sponge has a porous structure capable of absorbing liquid in 30-40 times more than its weight, so it can be used to stop bleeding, and the presence of antibiotic gives it antibacterial and anti-inflammatory properties. However, the sponge is not practically stimulates fibrinopeptide the application to the burn surface of the fabric. In addition, the presence of sultanol in the composition of the sponge disrupts the process of stabilizing the foam. Sultanol retains water in the gelatin solution with the formation of gelling clots and in the target product data plots frozen total weight that SS="ptx2">It should also be noted that the presence of technology for famous sponge frozen foam often leads to violation of the porous structure, it begins to "tear" and the plates don't work. To eliminate the above disadvantages has been tasked with the development of the composition of the sponge on a gelatin basis, with a wider range of therapeutic action that expands the Arsenal of tools with hemostatic, antiseptic and wound-healing activity in the high quality of the target product. The problem is solved by a new composition of sponges containing gelatin as a base, active ingredient, furatsilin and additionally methyluracil in the following ratio, wt.%: The active ingredient 5-6 Methyluracil 20-25 Furatsilin 0.5 Gelatin to 100 As the active component, preferably sponge contains kanamycin sulfate, however, this does not preclude the use of other broad-spectrum antibiotics such as gentamicin, lincomycin, etc. that can be used in medical practice for burns, purulent wounds, sores and ulcers and bleeding. In addition, the sponge may additionally contain calcium chloride in amounts up to 0.5% relative to gelatin that provides the induction process of thrombus formation, promotes natural coagulation and accelerate stop the bleeding. The introduction of advanced composition sponge furatsilina contributes to the suppression factor resistivity of microorganisms to antibiotics. This allows you to reduce the amount of antibiotic, in particular kanamycin sulfate to the selected ratio of 5-6%, which corresponds to its activity 30345-41000 UNITS and to provide local treatment sponge long nezaj the ex stages of the repair process. To improve the structure and stabilization of gelatin sponge in its composition can be introduced formaldehyde in an amount of not more than 3 wt.% in relation to gelatine. High therapeutic efficacy, as shown by numerous studies, is conditioned by the totality of its components in the composition of the sponge, and the optimal ratio. The quantitative content of essential medicines, in particular active component and methyluracil, was calculated experimentally on the basis of the data on their application in practical medicine. Reducing their quantitative content leads to a decrease in therapeutic effect and change in the structure of the foamed product, and the increase is limited to individual sensitivity and allergic manifestations. In addition, the increase in the content of methyluracil conducts to the formation of unsightly scars. As a result of these studies revealed the ability of the drug to normalize the reparative processes using the products of its degradation in the infected wound. Offer hemostatic, antiseptic and wound healing sponge receive the following abrazolast solution at room temperature for swelling on 18 PM Then the obtained solution of gelatin in furatsilina heated until the gelatin has dissolved and injected additives - calcium chloride and formaldehyde. The resulting mixture is foamed to increase ~ 3 times and impose solutions of the antibiotic and methyluracil in distilled water. Churn for another 5-7 min to obtain a froth and poured into chilled kootam. Drying of the product is carried out at room temperature and normal humidity for 3 days (on prototype up to 5 days). The product is then placed in a vacuum dryer for final drying sponge for 30 hours at a temperature of from 45 CELSIUS to minus 50°C. the Finished dry product is cut into sheets of appropriate size, for example from 200 to 300 mm and 1010 mm, Packed in paper bags and sterilized. Examples of embodiment of the invention. Example 1. In the prepared solution furatsilina (3000 ml of distilled water taken 0.24 g furatsilina) introduced 100 g of gelatin, pre-heated at 100C, and leave the solution for the swelling of gelatin for 18 h the resulting solution was heated until the gelatin has dissolved and injected additive - 0.18 g of calcium chloride and 1.44 g of formaldehyde. Policeman kanamycin sulfate, containing 1 g or 0.5 g dissolved in 2 ml of distilled water) and mix. Then add 20 g methyluracil, dissolved in 20 ml of distilled water, churn for another 5-7 min to obtain a froth and poured into chilled kootam. The product drying is carried out at room temperature and normal humidity for three days. The product is then placed in a vacuum dryer for final drying sponge for 30 h at the temperature from 45 CELSIUS to minus 50C. The finished dry product is cut into sheets of a given size with a weight of 0.65 to 0.85 g, Packed in paper bags and sterilized by dry heat at 120C for 15 minutes Example 2. Getting hemostatic, antiseptic and vulnerary sponges carried out analogously to example 1, with the following component (d): gelatin - 120, methyluracil - 20, furatsilina - 0.4, formaldehyde - 5. The increase in the content of gelatin and formaldehyde increases the rigidity of the sponge, which allows to stabilize the plate on a heavily bleeding wounds. Example 3. Getting hemostatic, antiseptic and vulnerary sponges carried out analogously to example 1, when the following have committed formaldehyde from the sponge and the increase in the content of methyluracil allows to obtain more plastic sponge, that gives the possibility to simulate a wound on the surface on any parts of the body, particularly the limbs. Having a highly homogeneous surface, a gelatin sponge has a fast atraumatic hemostatic effect and high absorbency, which can exceed its own weight in 45-50 times, which allows to use the sponge if heavy bleeding occurs. Increased absorption capacity and low-acid composition, destructive acting on albumin and globulin of the blood, help stop blood through 2-8 min, which reduces blood loss in 4 or more times. Thus, the proposed sponge on a gelatin basis for its hemostatic properties comparable with foreign sample, in particular with absorbable hemostatic sponge "Spongostan and far exceeds it in healing. Clinical studies have also confirmed its high therapeutic efficacy for use in surgical, dental and therapeutic purposes. Studies have been conducted in the treatment offered by the sponge patients with superficial and deep burns. The total number of patients that were treated - 97 bolny funds. So in 16 patients with II degree burns area of 3.5% of the body surface at the beginning of treatment sponge on day 2 after injury complete epithelialization of wounds occurred on the 8th after injury. While in 12 patients with II degree burns on the area of 2.5% of body surface, at the beginning of treatment sponge on the 8th day after injury, the wound was completely kapitalizirovana at 13-14 days after injury. The same was found in 69 patients with burns I-III And class. Similar results were obtained in the treatment of 14 patients with burns I-III And degrees ranging from 11% to 20%, including burns III And 4% of the body surface. At the beginning of treatment sponge on day 4 after injury, the wound healing was on 19-20-th day after receipt of burns, and in 8 patients with burn area III And 4% of the body surface and at the beginning of treatment sponge on 11-12 day healing was observed at 31-34-th day since the injury. Analysis of treatment outcomes of patients with extensive deep burns showed that they depended not only on treatment, but also from area deep burn and the General condition of the affected. It was found that the treatment offered by the sponge patients with burns III 5-IV degree 21-23% of the body surface, the total area of burns 43-51,5% of all patients were discharged on viscomi, with an area of deep (III B-IV degree) burn of 17.5-19% of the body surface, the total area of burn 31-40% died during septicaemia at 31-33 day after injury. In addition, a study was made possible and efficient application sponge as a biological coating in patients with AVANTASIA in purulent wound. The analysis of the results showed the advantage of using the sponge with antiseptic antibiotic, especially in patients with AVANTASIA in purulent wound, when the inability of the suturing warned the formation of new fistula hollow bodies, accelerated healing processes and wound healing. Thus, clinical and experimental studies established antiseptic and wound-healing hemostatic sponges showed its high therapeutic and hemostatic efficiency that allows it to be recommended for widespread use in clinical practice in various fields of medicine. In addition, it should be noted that in comparison with the prototype of a new sponge has a wider range of actions, greatly simplifying its manufacturing technology by eliminating the stage of low-temperature drying, and increases the quality of the target product. 1. Antiseptic and hemostatic wound sponge containing gelatin as the basis, the active ingredient and furatsilin, characterized in that it further comprises methyluracil in the following ratio, wt.%: The active ingredient 5-6 Methyluracil 20-25 Furatsilin 0.5 Gelatin To 100 2. Sponge under item 1, characterized in that it as the active component preferably contains kanamycin sulfate. 3. Sponge under item 1, characterized in that it additionally contains calcium chloride in an amount of not more than 0.5 wt.% in relation to gelatine.
|
